Although liraglutide, verapamil, and golimumab have each demonstrated benefits in subjects with type 1 diabetes and residual insulin secretion, we found no evidence that short-term treatment with these agents stimulates transient insulin secretion in people with C-peptide negative type 1 diabetes. Here, INS is linked to type 1 diabetes mellitus.